Dapagliflozin and sacubitril on myocardial microperfusion in patients with post-acute myocardial infarction heart failure and type 2 diabetes

Table 5 Comparison of correlation factors between two groups

Item	Control group (n = 47)		t	P value	Observation group (n = 51)		t	P value
	Before treatment	After treatment			Before treatment	After treatment
NT-proBNP (pg/mL)	3624.74 ± 475.69	2015.23 ± 286.31a	20.00	< 0.01	3652.05 ± 439.87	1502.65 ± 255.87a,c	26.28	< 0.01
NT-proANP (ng/mL)	3526.02 ± 412.05	1875.52 ± 241.02a	24.39	< 0.01	3498.74 ± 397.86	1415.69 ± 213.05a,c	31.17	< 0.01
GDF-15 (g/L)	3.02 ± 0.85	1.21 ± 0.56a	12.91	< 0.01	2.97 ± 0.93	0.87 ± 0.43a,c	15.19	< 0.01
hs-CRP (mg/L)	13.56 ± 2.58	8.77 ± 1.94a	10.20	< 0.01	13.42 ± 2.67	6.54 ± 1.56a,c	20.60	< 0.01

^aP < 0.05 vs before treatment.

^cP < 0.05 vs control group.

NT-proBNP: N-terminal prohormone of brain natriuretic peptide; NT-proANP: N-terminal pro-atrial natriuretic peptide; GDF-15: Growth differentiation factor-15; hs-CRP: High-sensitivity C-reactive protein.